Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ENDOCYTE INC | v336098_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | February 25, 2013 |
| Endocyte, Inc. | ||
| (Exact name of registrant as specified in its charter) |
| Delaware | 001-35050 | 35-1969-140 | ||
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
|
3000 Kent Avenue, Suite A1-100, West |
47906 | |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | 765-463-7175 |
| Not Applicable | ||
| Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On February 25, 2013, Endocyte, Inc. (the "Company") announced its results of operations for the three and twelve months ended December 31, 2012. A copy of the Company's earnings release is furnished herewith as Exhibit 99.1.
The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated February 25, 2013 relating to Endocyte's fourth quarter 2012 results of operations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Endocyte, Inc. | |||
| February 25, 2013 | By: | /s/ Michael A. Sherman | |
| Name: Michael A. Sherman | |||
| Title: Chief Financial Officer | |||
Exhibit Index
| Exhibit No. |
Description | |
| 99.1 | Exhibit 99.1 Earnings Release |